Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/S ratio is N/A as of 2026-10-06T14:41:37.924Z.
Calculation as of: 2026-10-06T14:41:37.924Z.
Quote observation: 2026-10-06T14:28:24.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 47abfa0c1c9b7ee8852b85727c09e566e291b91d06fb52154cb7b2e7f04347a4
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
N/A
Drugs Made In America Acquisition II Corp. Ordinary Shares
Market Cap
$648.92M
PS Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$648.42M
PS Ratio
3.79
TTM Avg
4.39
3Y Avg
5.25
5Y Avg
5.75
Market Cap
$656.27M
PS Ratio
N/A
TTM Avg
2.45
3Y Avg
2.45
5Y Avg
2.45
Market Cap
$635.96M
PS Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$628.99M
PS Ratio
0.80
TTM Avg
2.23
3Y Avg
1.97
5Y Avg
2.74
Market Cap
$669.32M
PS Ratio
6.32
TTM Avg
8.35
3Y Avg
9.39
5Y Avg
9.39
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Drugs Made In America Acquisition II Corp. Ordinary Shares (DMII) | $648.92M | N/A | N/A | N/A | N/A |
| New Mountain Finance Corporation (NMFC)vs › | $648.42M | 3.79 | 4.39 | 5.25 | 5.75 |
| Capital Bancorp, Inc. (CBNK)vs › | $653.97M | 2.23 | 1.78 | 1.73 | 1.75 |
| ACNB Corporation (ACNB)vs › | $656.52M | 3.28 | 2.97 | 2.85 | 2.81 |
| CoinShares PLC Ordinary Shares (CSHR)vs › | $656.27M | N/A | 2.45 | 2.45 | 2.45 |
| BlackRock Multi-Sector Income Trust (BIT)vs › | $635.96M | N/A | N/A | N/A | N/A |
| Hypoport SE (HYPOF)vs › | $630.67M | 0.88 | 1.76 | 2.26 | 3.07 |
| Coastal Financial Corporation (CCB)vs › | $628.99M | 0.80 | 2.23 | 1.97 | 2.74 |
| Gladstone Investment Corporation (GAINI)vs › | $669.32M | 6.32 | 8.35 | 9.39 | 9.39 |
| American Bitcoin Corp (ABTC)vs › | $626.16M | 2.30 | 8.40 | 19.70 | 13.17 |
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-18 |
| Q4 FY2025Period ended 2025-12-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-04-15 |
| Q1 FY2026Period ended 2026-03-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-14 |
| Q2 FY2026Period ended 2026-06-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-14 |
| TTM revenue | $0 |
The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
P/S Ratio
N/A
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
